Picano E, Landi P, Bolognese L, Chiarandà G, Chiarella F, Seveso G, Sclavo M G, Gandolfo N, Previtali M, Orlandini A
CNR, Institute of Clinical Physiology, Pisa, Italy.
Am J Med. 1993 Dec;95(6):608-18. doi: 10.1016/0002-9343(93)90357-u.
To determine the prognostic capability of the dipyridamole echocardiography test (DET) early after an acute myocardial infarction.
On the basis of 11 different echocardiographic laboratories, all with established experience in stress echocardiography and fulfilling quality-control requirements for stress echocardiographic readings, 925 patients were evaluated after a mean of 10 days from an acute myocardial infarction and followed up for a mean of 14 months.
During the follow-up, there were 34 deaths and 37 nonfatal myocardial infarctions; 104 patients developed class III or IV angina and 149 had coronary revascularization procedures (bypass or angioplasty). Considering all spontaneous events (angina, reinfarction, and death), the most important univariate predictor was the presence of an inducible wall motion abnormality after dipyridamole administration (chi 2 = 45.8). With a Cox analysis, echocardiographic positivity, age, and male gender were found to have an independent and additive value. Considering survival (and, therefore, death as the only event), age was the most meaningful parameter, followed by the wall motion score index during dipyridamole administration (chi 2 = 12.1). Among other parameters, the resting wall motion score index was a significant predictor of death. In a multivariate analysis, the prognostic contributions of age (relative risk estimate = 1.08) and wall motion score index during dipyridamole administration (relative risk estimate = 4.1) were independent and additive. In particular, considering death only, the event rate was 2% in patients with negative DET results, 4% in patients with positive high-dose DET results, and 7% in patients with positive low-dose DET results.
DET is feasible and safe early after uncomplicated myocardial infarction and allows effective risk stratification on the basis of the presence, severity, extent, and timing of the induced dyssynergy.
确定急性心肌梗死后早期双嘧达莫超声心动图试验(DET)的预后评估能力。
基于11个不同的超声心动图实验室,所有实验室均有应激超声心动图方面的既定经验且满足应激超声心动图读数的质量控制要求,对925例患者进行了评估,这些患者在急性心肌梗死后平均10天接受评估,并平均随访14个月。
在随访期间,有34例死亡和37例非致命性心肌梗死;104例患者出现Ⅲ或Ⅳ级心绞痛,149例患者接受了冠状动脉血运重建术(搭桥或血管成形术)。考虑所有自发事件(心绞痛、再梗死和死亡),最重要的单变量预测因素是双嘧达莫给药后出现可诱导的室壁运动异常(χ² = 45.8)。通过Cox分析,发现超声心动图阳性、年龄和男性性别具有独立且相加的价值。考虑生存情况(因此将死亡作为唯一事件),年龄是最有意义的参数,其次是双嘧达莫给药期间的室壁运动评分指数(χ² = 12.1)。在其他参数中,静息室壁运动评分指数是死亡的重要预测因素。在多变量分析中,年龄(相对风险估计值 = 1.08)和双嘧达莫给药期间的室壁运动评分指数(相对风险估计值 = 4.1)的预后贡献是独立且相加的。特别是仅考虑死亡情况时,DET结果阴性的患者事件发生率为2%,高剂量DET结果阳性的患者为4%,低剂量DET结果阳性的患者为7%。
在无并发症的心肌梗死后早期,DET是可行且安全的,并能根据诱导性协同失调的存在、严重程度、范围和发生时间进行有效的风险分层。